|
Other anticoagulants
Citations 61-70 of 93 total displayed.
|
Past content
(since Jan 2001):
|
- Articles
Soluble CD40 Ligand in Pulmonary Arterial Hypertension. Possible Pathogenic Role of the Interaction Between Platelets and Endothelial Cells
- Jan K. Damås, Kari Otterdal, Arne Yndestad, Halfdan Aass, Nils O. Solum, Stig S. Frøland, Svein Simonsen, Pål Aukrust, and Arne K. Andreassen
Circulation published August 9, 2004, doi:10.1161/01.CIR.0000139859.68513.FC
[Abstract]
- Reviews: Current Perspectives
Should C-Reactive Protein Be Added to Metabolic Syndrome and to Assessment of Global Cardiovascular Risk?
- Paul M Ridker, Peter W.F. Wilson, and Scott M. Grundy
Circulation 2004;109:2818-2825, doi:10.1161/01.CIR.0000132467.45278.59
[Abstract]
[Full text]
- Correspondence
Lepirudin Anaphylaxis and Kounis Syndrome • Response
- Constantinos M. Koutsojannis, Nicholas G. Kounis, A. Greinacher, N. Lubenow, and P. Eichler
Circulation 2004;109:e315, doi:10.1161/01.CIR.0000129324.33507.DC
[Full text]
- Clinician Update
Pulmonary Embolism After Coronary Artery Bypass Grafting
- Samuel Z. Goldhaber and U. Joseph Schoepf
Circulation 2004;109:2712-2715, doi:10.1161/01.CIR.0000132616.89315.34
[Full text]
- Clinical Investigations and Reports
Safety and Efficacy of Enoxaparin Compared With Unfractionated Heparin and Oral Anticoagulants for Prevention of Thromboembolic Complications in Cardioversion of Nonvalvular Atrial Fibrillation: The Anticoagulation in Cardioversion using Enoxaparin (ACE) Trial
- Christoph Stellbrink, Uwe Nixdorff, Thomas Hofmann, Walter Lehmacher, Werner Günther Daniel, Peter Hanrath, Christoph Geller, Andreas Mügge, Walter Sehnert, Caroline Schmidt-Lucke, Jan-André Schmidt-Lucke on Behalf of the ACE (Anticoagulation in Cardioversion using Enoxaparin) Study Group
Circulation 2004;109:997-1003; published online before print as doi:10.1161/01.CIR.0000120509.64740.DC
[Abstract]
[Full text]
- Articles
Safety and Efficacy of Enoxaparin Compared With Unfractionated Heparin and Oral Anticoagulants for Prevention of Thromboembolic Complications in Cardioversion of Nonvalvular Atrial Fibrillation. The Anticoagulation in Cardioversion using Enoxaparin (ACE) Trial
- Christoph Stellbrink, Uwe Nixdorff, Thomas Hofmann, Walter Lehmacher, Werner Günther Daniel, Peter Hanrath, Christoph Geller, Andreas Mügge, Walter Sehnert, Caroline Schmidt-Lucke, Jan-André Schmidt-Lucke on Behalf of the ACE (Anticoagulation in Cardioversion using Enoxaparin) Study Group
Circulation published February 16, 2004, doi:10.1161/01.CIR.0000120509.64740.DC
[Abstract]
- Clinical Investigations and Reports
High Plasma Heparin Cofactor II Activity Is Associated With Reduced Incidence of In-Stent Restenosis After Percutaneous Coronary Intervention
- Nobuyuki Takamori, Hiroyuki Azuma, Midori Kato, Shunji Hashizume, Ken-ichi Aihara, Masashi Akaike, Katsuya Tamura, and Toshio Matsumoto
Circulation 2004;109:481-486; published online before print as doi:10.1161/01.CIR.0000109695.39671.37
[Abstract]
[Full text]
- Articles
High Plasma Heparin Cofactor II Activity Is Associated With Reduced Incidence of In-Stent Restenosis After Percutaneous Coronary Intervention
- Nobuyuki Takamori, Hiroyuki Azuma, Midori Kato, Shunji Hashizume, Ken-ichi Aihara, Masashi Akaike, Katsuya Tamura, and Toshio Matsumoto
Circulation published January 26, 2004, doi:10.1161/01.CIR.0000109695.39671.37
[Abstract]
- Correspondence
Prosthetic Heart Valves and Pregnancy • Response
- Claire McLintock, Robyn A. North, Harvey D. White, Lynne Hung, and Shahbudin H. Rahimtoola
Circulation 2003;108:e159-160e, doi:10.1161/01.CIR.0000102966.93922.B1
[Full text]
- Review: Clinical Cardiology: New Frontiers
Acute Pulmonary Embolism: Part II: Risk Stratification, Treatment, and Prevention
- Samuel Z. Goldhaber and C. Gregory Elliott
Circulation 2003;108:2834-2838, doi:10.1161/01.CIR.0000098427.74047.42
[Full text]
|
|
